Therapeutic Trial:
Therapeutic efficacy of the Serpens Species Bacterin vaccine was first demonstrated in a prospectively controlled, double blind field trial involving more than 35 clinically lame, wart bearing cows in each of two groups: vaccinates and controls. Disease progression was ameliorated more rapidly in vaccinated animals than in controls. Following the second and third doses the lesions stabilized. By six weeks post vaccination, vaccinates showed a marked reduction in total lesion area compared to controls.
Prophylactic Trial:
In a preventative trial, 59 Holstein cows were divided into two equal groups based upon age, parity, DIM, production, and SCC. Vaccination status was assigned randomly to each group (29 vaccinates, 30 unvaccinated controls.) Animals were given three doses of vaccine at monthly intervals. Prevalence of lesions in each group was determined by visual inspection at the start of the trial, and the incidence of new cases was determined at weekly intervals. Over a period of 33 weeks only 11 percent of the vaccinates developed new lesions (none following the third dose.) In contrast, over 50 percent of control animals developed new lesions over the same period.
Independent Trial:
In an independently administered trial, the Serpens Species Bacterin was tested for therapeutic effectiveness in a whole herd program. A total of 592 cows were randomly segregated into vaccinate and control groups (291 vaccinates, 301 unvaccinated controls.) The vaccinate group received three doses at monthly intervals. Visual evaluation of animals to determine PDD status was done at the date of the first vaccination and at one month after administration of the third dose. At the onset of the trial, 77 vaccinates and 84 controls were affected with PDD. One month following the third vaccination, seven vaccinates had lesions. In contrast, the number of affected controls had risen to 87.
Home Contact Us Products Schedule Employment